Status:
TERMINATED
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Mild Cognitive Impairment
Alzheimer Disease
Eligibility:
All Genders
45-90 years
Phase:
PHASE2
Brief Summary
The purpose of this platform study was to evaluate the effect of anti-inflammatory agents on cognition in early Alzheimer's disease. Additionally, the safety and tolerability and their effects on cent...
Detailed Description
This was a randomized, placebo-controlled, participant- and investigator-blinded study in participants with either mild cognitive impairment or mild Alzheimer's disease with evidence of peripheral inf...
Eligibility Criteria
Inclusion
- Male or female, age ≥ 45 years and ≤ 90 years at the time of signing the informed consent;
- Participant has a reliable study partner or caregiver can accompany the participant to all visits;
- A diagnosis of probable MCI due to AD or mild AD according to the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria;
- Confirmed amyloid and tau positivity via CSF sampling performed at screening;
- Mini-Mental State Examination (MMSE) total score of 20 to 24 (inclusive) at screening; OR, MMSE total score of 25-30 (inclusive) plus a DSST score at least 0.5 standard deviation (SD) below normative data at screening.
Exclusion
- Use of an investigational agent or an approved product with the intent to modulate inflammation or modulate the course of AD (e.g., Tau ASOs, gene therapy, amyloid or tau vaccine):
- Previous use of small molecules is allowed if discontinued for at least five half-lives, or at least 30 days from when the expected pharmacodynamic effect has returned to baseline prior to screening, whichever is longer
- Previous use of monoclonal or polyclonal antibodies or other biologics is allowed if discontinued for at least five half-lives prior to screening
- Current medical or neurological condition that might impact cognition or performance on cognitive assessments, e.g., MCI not due to AD, non-Alzheimer dementia, Huntington's disease, Parkinson's disease, stroke, schizophrenia, bipolar disorder, active major depression, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), active seizure disorder, or history of traumatic brain injury associated with loss of consciousness and ongoing residual transient or permanent neurological signs/symptoms including cognitive deficits, and/or associated with skull fracture;
- Diagnosis of vascular dementia prior to screening (e.g., modified Hachinski Ischaemic Scale score \> 6 or those who meet the NINDS AIREN criteria for vascular dementia);
Key Trial Info
Start Date :
October 28 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 7 2024
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT04795466
Start Date
October 28 2021
End Date
March 7 2024
Last Update
October 16 2025
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Charlestown, Massachusetts, United States, 02129
2
SUNY at Stony Brook
Stony Brook, New York, United States, 11794-8161
3
Novartis Investigative Site
Kuopio, Finland, 70210
4
Novartis Investigative Site
Turku, Finland, 20520